Scilex Holding Company

SCLX

US80880W1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8805 ^USD	+2.29%		-1.93%	-56.84%

Apr. 16	Scilex Issues Preliminary Q1 Sales Results for ZTlido	MT
Mar. 20	Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	MT

Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023

March 12, 2024 at 06:05 am EDT

Scilex Holding Company reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 46.74 million compared to USD 38.03 million a year ago. Net loss was USD 114.33 million compared to USD 23.36 million a year ago.

Basic loss per share from continuing operations was USD 1.28 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 1.28 compared to USD 0.17 a year ago.

Latest news about Scilex Holding Company

Scilex Issues Preliminary Q1 Sales Results for ZTlido	Apr. 16	MT
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	Mar. 20	MT
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20	MT
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed	Mar. 20	CI
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada	Mar. 18	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Top Midday Decliners	Mar. 01	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	Mar. 01	MT
US Futures Remain Flat as Investors Await Raft of Economic Data	Mar. 01	MT
Scilex Holding Signs Underwriting Agreement for $10 Million Bought Deal Offering	Mar. 01	MT
Scilex Files $500 Million Mixed-Securities Shelf	Jan. 09	MT
Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023	Jan. 02	CI
Scilex Files New Drug Submission for Migraine Treatment Approval in Canada	Dec. 26	MT
Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	Dec. 26	CI
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing	Dec. 19	CI
Scilex Says US Pharmacy Chain to Stock Elyxyb	Dec. 15	MT
Scilex Holding Company Announces Major Pharmacy Initiative with the National Leading Pharmacy Chain to Stock ELYXYB® in Most of Their Stores Throughout the U.S	Dec. 15	CI
Scilex Holding Company Announces Expanded Access to Elyxyb® by the Execution of First Elyxyb® Insurance Coverage Agreement with One of the Top Three National Pbms (Pharmacy Benefit Manager) for Its Medicare Population	Dec. 12	CI
Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List in Two New States: One Midwestern and One Southern State	Dec. 06	CI
Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List of the State of the State of Tennessee	Dec. 04	CI
Scilex Holding Company Reports Sales Results for the Month and Year-To-Date Ended November 30, 2023	Dec. 01	CI
Scilex Says US FDA Successfully Completes Audit of ZTlido Plant in Japan	Nov. 30	MT
Scilex Holding Company Announces Successful Fda Audit of Enhanced Ztlido®? Manufacturing Facility in Japan	Nov. 30	CI
Scilex Signs Agreement With US Pharmacy Chain to Stock Elyxyb in More Than 500 Stores	Nov. 28	MT

Chart Scilex Holding Company

Duration

Period

More charts

Company Profile

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

Sector

Pharmaceuticals

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Scilex Holding Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8805 USD

Average target price

6.833 USD

Spread / Average Target

+676.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SCILEX HOLDING COMPANY	-56.84%	107M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals